Oscar Health, Inc.

(a) None.

(b) None.

(c) On August 8, 2025, each of the executive officers listed in the table below, in accordance with the Company’s standard practice for employees and executive officers, entered into the Company’s form of sell-to-cover instruction that is intended to satisfy the affirmative defense of Rule 10b5-1(c), providing for sales of a number of shares of Class A common stock as is necessary to cover tax withholding obligations incurred in connection with the vesting or settlement of restricted stock units held by such executive officer. The instruction will remain in effect so long as the executive is subject to such tax obligations, unless earlier terminated. The total number of shares of Class A common stock that may be sold pursuant to the instruction is not determinable.

On September 23, 2025, Mario Schlosser, the Company’s Co-Founder and Chief Technology Officer, entered into a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c). Mr. Schlosser’s plan is for the sale of up to 127,003 shares of Class A common stock, and the sale of 246,693 shares of Class B common stock, through June 30, 2026. The plan terminates on the earlier of the date all the shares under the plan are sold and June 30, 2026. No trades will commence under the plan until after the expiration of the applicable cooling off period on December 22, 2025.